Healthcare & Insurance
CV Sciences, Inc. Wins 2019 NEXTY Award
Company’s industry-dominating hemp extract brand, PlusCBD Oil™, wins Consumer Choice Award at Natural Products Expo East SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Magnusson)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:35 pm Sampo plc: Managers’ Transactions (Magnusson) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Lapveteläinen)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:35 pm Sampo plc: Managers’ Transactions (Lapveteläinen) Sampo plc (business code 0142213-3) has received the following notification under Article
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Martinsen)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:35 pm Sampo plc: Managers’ Transactions (Martinsen) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Wennerklint)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:30 pm Sampo plc: Managers’ Transactions (Wennerklint) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Thorsrud)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:30 pm Sampo plc: Managers’ Transactions (Thorsrud) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Niemisvirta)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:30 pm Sampo plc: Managers’ Transactions (Niemisvirta) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the
Tuesday, September 17, 2019
Sampo plc: Managers’ Transactions (Stadigh)
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:30 pm Sampo plc: Managers’ Transactions (Stadigh) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the
Tuesday, September 17, 2019
Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™
SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti
Tuesday, September 17, 2019
Avricore Health and Clinart MENA Announce Interim Agreement for HealthTab™ + RASTR Network Middle East Expansion
VANCOUVER, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce that it has signed a first stage agreement in the form of a Letter of Intent (LOI) with Dubai based clinical research
Tuesday, September 17, 2019
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code. “We believe
Tuesday, September 17, 2019
KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will host one-on-one
Tuesday, September 17, 2019
Orphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event
Orphazyme A/SInvestor news No. 04/2019
Tuesday, September 17, 2019
Fujifilm Exercises License Option in GvHD
MELBOURNE, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that FUJIFILM Corporation (“Fujifilm”) has today exercised its license option in graft-versus-host
Tuesday, September 17, 2019
Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24,
Tuesday, September 17, 2019
Philips launches NightBalance, increasing therapy options for positional obstructive sleep apnea patients
September 17, 2019 Clinically-validated sleep position treatment provides a comfortable, easy-to-use alternative for positional obstructive sleep apnea patientsUpdates include wireless connectivity and new mobile app Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global
Tuesday, September 17, 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. The claims of the
Tuesday, September 17, 2019
Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with
- CNTX-4975 Phase 3 clinical development program fully enrolled - - VICTORY-1 pivotal and VICTORY-3 open-label topline results expected in Q1 2020; VICTORY-2 pivotal results expected in Q3 2020 - BOSTON, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused
Tuesday, September 17, 2019
Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr. Thomas Hayman,
Tuesday, September 17, 2019
